Rootrak Completes Cheonan Plant for Artificial Joint Production... Manufacturing FDA-Approved Products for the US Market

Establishment of Production System with Advanced Production Lines Including Sterilization and Packaging Processes
"Production Capacity Can Be Expanded Targeting Domestic and Overseas Markets Such as the US"

[Asia Economy Reporter Hyungsoo Park] Rootloc, a company specializing in artificial joints, announced on the 9th that it held a completion ceremony for its Cheonan factory, which produces artificial hip joint products approved by the U.S. Food and Drug Administration (FDA).

Rootloc's Cheonan factory has a self-production system that covers the entire artificial joint process, from MCT machining to polishing, sterilization, and packaging, as well as facilities for producing antibacterial bone cement. Rootloc is an affiliate of L&K Biomed.

Attendees at the Cheonan factory completion ceremony included Rootloc CEO Jongjin Park, Head of Production Daeseon Yoo, executives and employees, L&K Biomed CEO Geunju Park, Vice Chairman Seungwook Ki, Research Director Jonghoon Moon, and others. Additionally, Kwon Soonhaeng, Director of Gongju Hyundai Hospital, and executives and employees from partner companies such as Sung A Precision Industry and Cheonji Industry also participated.

Rootloc had been supplying products through outsourced production. With the completion of its own production plant, it is now ready to increase production volume to meet the growing order volume not only in the domestic market but also in the U.S. market.

At the completion ceremony, CEO Jongjin Park expressed, "There were considerable concerns about a small and medium-sized venture company deciding on a large-scale investment amid the global economic uncertainty caused by the COVID-19 pandemic." He added, "However, with the implementation of 'With COVID' and gradually emerging from the pandemic tunnel, demand for artificial joints is increasing, and the outlook is bright."

CEO Park emphasized, "As the saying goes, 'Crisis is opportunity.' The bold decision made during difficult times has allowed us to dream of a greater future. The Cheonan factory will serve as Rootloc's core competitiveness and a domestic production outpost for artificial joints."

Rootloc's Cheonan factory has established dedicated lines to enhance production efficiency. This allows for shortened product development time through dedicated research and development lines, thereby increasing customer satisfaction.

In addition to increased production volume due to expansion, the introduction of cutting-edge equipment such as MCT, polymer machining, short machines, and ultrasonic cleaners for efficient manufacturing of precision machined parts is expected to improve product quality.

Daeseon Yoo, Head of Production (Factory Manager), stated, "The Cheonan factory will increase production volume while reducing manufacturing costs through the introduction of the most advanced medical processing equipment in Korea. We will be able to respond quickly to various customer demands, and through this, increase customer loyalty to secure a competitive edge over competitors."

A company representative said, "Rootloc is currently applying for FDA approval for artificial hip joint products based on its FDA-approved technology in the artificial knee joint field," and added, "We have developed antibacterial bone cement to prevent postoperative complications caused by bacterial infections during artificial hip joint surgery, and plan to start sales by the end of this year."

Founded in 2014, Rootloc began developing and selling its self-developed artificial joint product, CentLoc, and is developing artificial joints tailored to the Korean body type. It succeeded in domesticating artificial joints in the domestic market, which had relied on foreign products. In March, it received the '2021 Korea Global Crown Award' International Division Corporate Award for its contribution to the localization of artificial joints.

This content was produced with the assistance of AI translation services.